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Abstract
Decitabine has been explored as a reduced-intensity therapy for older or unfit
patients with acute myeloid leukemia (AML). To better understand the risk of
infections during decitabine treatment, we retrospectively examined the culture
results from each infection-related serious adverse event that occurred among
85 AML and myelodysplastic syndromes (MDS) patients treated in a prospective
clinical study using 10-day cycles of decitabine at Washington University School
of Medicine. Culture results were available for 163 infection-related complications that occurred in 70 patients: 90 (55.2%) events were culture-negative, 32
(19.6%) were gram-positive bacteria, 20 (12.3%) were gram-negative bacteria,
12 (7.4%) were mixed, 6 (3.7%) were viral, 2 (1.2%) were fungal, and 1 (0.6%)
was mycobacterial. Infection-related mortality occurred in 3/24 (13%) of gram-
negative events, and 0/51 gram-positive events. On average, nearly one third of
patients experienced an infection-related complication with each cycle, and the
incidence did not decrease during later cycles. In summary, in patients receiving
10-day decitabine, infectious complications are common and may occur during
any cycle of therapy. Although febrile events are commonly culture-negative,
gram-positive infections are the most frequent source of culture-positive infections, but gram-negative infections represent a significant risk of mortality in
AML and MDS patients treated with decitabine.

work.

Introduction
Decitabine is a cytosine analog with S-
phase-
dependent
pharmacokinetics that is incorporated into DNA, but cannot be methylated [1–3]. Historically, it has yielded clinical
responses in ~25% of patients with acute myeloid leukemia
(AML) or myelodysplastic syndromes (MDS) across diverse
clinical trials, although response rates may be higher using
a 10-
day versus 5-
day approach [4–6]. In general,
2814

decitabine is well tolerated and can be given in the outpatient setting.
Decitabine treatment is associated with infection complications and readmission for neutropenic fevers [5, 7,
8]. Limited data exist concerning the types of infections
that occur in AML and MDS patients treated with
decitabine.
We recently completed a study of AML and MDS
patients treated with decitabine administered in 10 daily
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doses per cycle [5]. Similar to others [6], we observed
modestly higher response rates using the 10-day regimen
(46%) versus published results from 5-
day regimens
(17–32%) [8–11], and the majority of Common
Terminology Criteria for Adverse Events (CTCAE)-defined
significant adverse events (SAEs) we observed were associated with infectious complications and readmission for
neutropenic fevers [5]. We also observed that response
correlated with the presence of mutations in TP53 [5].
Antibiotic prophylaxis has been controversial during
AML chemotherapy (for both decitabine and cytarabine-
based treatments), and the benefits of prophylaxis are
unclear.
In this study, we reviewed each infection-related SAE
observed among 85 patients to determine whether the
infectious complications observed during decitabine treatment might be different from the complications of more
intensive regimens, and whether specific bacteria were
commonly observed that might be amenable to alternative
prophylaxis.

Patients and Methods
Study design
We reviewed all CTCAE (version 4.0) grade 3–5 SAEs
associated with infectious complications in 85 patients
with AML or MDS who were enrolled between April 2013
and November 2015 on a clinical study at Washington
University School of Medicine (NCT01687400) [5]. Of
these, 70 patients had infection-related events with documented culture results that could be retrospectively evaluated. This study was approved by our institutional review
board and conducted in accordance with the provisions
of the Declaration of Helsinki. Response evaluation and
molecular end-points have been previously published [5].

Treatment
Decitabine was administered intravenously at a dose of
20 mg/m2 of body surface area per day in 28-day cycles.
Initial cycles were given on consecutive days 1–10. Once
patients achieved blasts <5%, they could reduce the dosing to days 1–5. After two cycles with dosing on days
1–5, the dose could be reduced further to days 1–3.
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according to commonly accepted guidelines. The diagnostic
work-
up in case of fever included collection of blood
cultures from central venous catheters and peripheral vein
and collection of nasal, pharyngeal, and anal swab. Standard
chest radiographs were obtained at hospital admission and
if clinically indicated. Cytomegalovirus (CMV) reactivation
was not routinely tested. Prompt empiric first-line therapies
consisted of cephalosporin, penicillin, or carbapenem antibiotics. Vancomycin was added if fever persisted for
48–72 h and at least one of the following clinical findings
was met: clinically suspected serious catheter-related infections, known colonization with penicillin-and
cephalosporin-
resistant pneumococci or methicillin-
resistant Staphylococcus aureus, positive blood cultures
for gram-positive bacteria before the final identification,
hypotension or other evidence of cardiovascular impairment. An azole or echinocandin was given empirically if
the patient did not respond to antibiotic therapy within
5–7 days. Modifications of the antibiotic therapy were
made on the basis of results of cultures and susceptibilities of microorganisms to antimicrobial agents.

Assessment of infection incidence and
outcome
Each recorded infection-related serious adverse event was
reviewed. Fever was considered as a single temperature
measurement of 38.4°C or 38.0°C over at least 1 h, in
the absence of obvious environmental causes.
Neutropenia was defined as an absolute neutrophil count
(ANC) less than 1.0 × 109/L. ANC was further categorized
according to whether they were <0.5 × 109/L or
<0.1 × 109/L at the onset of febrile episodes.
The causative agent, when identified, was classified as
bacterial (gram-positive, gram-negative, or mycobacterial),
fungal (Candida species, Aspergillus species, or other), or
viral (varicella zoster virus, herpes simplex virus [HSV]).
The site of infection was classified as blood (bacteremia),
skin and/or soft tissues, catheter-
related blood stream
infection, gastrointestinal (GI) tract, upper respiratory tract
(pharyngitis, sinusitis, rhinitis), lower respiratory tract
(pneumonia or bronchitis), urinary tract or joint/bone
(septic arthritis, osteomyelitis).
The outcome of infections for each patient was determined at the completion of the antimicrobial therapy. All
patients who died of infection were considered a failure.

Antimicrobial therapy
Prophylactic antimicrobial therapy was recommended, but
not stipulated as part of the study. Recommended prophylaxis consisted of acyclovir, ciprofloxacin, and fluconazole.
Patients who developed infection-
related complications
were treated with antimicrobial and supportive therapy

© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Statistical analysis
Data were analyzed through November 2016. Statistical
analysis was performed using SPSS program, version 24
(IBM, Chicago, IL). Univariate analysis (Fisher exact test
and Pearson chi-square T-test) was used for assessment
2815
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of infection incidence. P < 0.05 was considered statistically significant. The distribution of overall survival was
described using Kaplan–Meier curves and compared by
log-rank test. Survival analysis was performed using Prism
5 (GraphPad, San Diego, CA).

Results
Patients
A total number of 282 cycles of decitabine were administered to 85 patients with AML or MDS (Table 1). Fifty
patients were males (58.8%) and 35 were females (41.2%).
The median age of the patient population was 74 years
(range: 31–89 years). The median number of cycles received
was 2 (range 0.5–17). Two hundred and forty-eight hospital admissions following the administration of decitabine
were reviewed. Of these admissions, 65.7% were for febrile
episodes or infections (total of 163 admissions). The 30-
day mortality was 2.4%, the 60-day mortality was 19%,
and the 6-month survival was 63.5%. The clinical features
of patients with and without infection-related events are
shown in Table 1.

Effect of clinical factors
Clinical features were correlated with the incidence of
infection-
related SAEs (gender, age, performance status,
disease, response, and cycles completed). The median and
the mode number of infection-related SAEs per patient
in each subgroup was 1 (Table 1).
The incidence of infection-related SAEs was correlated
with the cycle number (Fig. 1A). On average, within each
cycle, approximately one third of patients receiving that
cycle experienced an infection-related SAE, and we observed
no consistent reduction in incidence during higher numbered cycles (i.e., cycles 4–9). Overall, the median survival
of the cohort was 318 days. Counterintuitively, patients
without an infection-
related SAE had shorter survival
(median 104 days vs. 446, 354, and 318 days for patients
with 0, 1, 2, or 3 or more SAEs, respectively), perhaps
because they did not remain on therapy long enough to
experience a complication (Fig. 1B).
In a univariate analysis comparing patients who had no
infections versus those who had one or more, patients with
younger age (age <70) tended to have a higher incidence
of infections. However, older patients had shorter survival,
and this may account for the disproportionate number of
older patients without an infection-related event (Fig. 1C).
Nevertheless, the difference in infection incidence between
the two groups (>70 vs. <70) did not reach a statistical
significance (P = 0.129). Likewise, compared to infections
incidence in AML patients (77.5%), a higher incidence of
2816
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Table 1. Clinical data.
Characteristic

Gender
Male
Female
Age
<40
40–60
>60
Performance status
0
1
2
Unknown
Disease
AML
MDS
Response
CR
CRi/mCR
PR/SD/PD
Not evaluable
Cycles completed
<1
1
2
3
>3
Total

Number of infection-related SAEs
2

Totals

0

1

>2

12
2

18
16

8
8

12
9

50
35

0
0
14

1
4
29

0
2
14

1
1
19

2
7
76

5
5
4
0

11
13
9
1

6
9
1
0

4
13
4
0

26
40
18
1

13
1

19
15

11
5

15
6

58
27

2
5
3
4

4
13
11
6

1
8
5
2

2
10
8
1

9
36
27
13

4
2
4
0
4
14

4
8
8
4
10
34

2
3
6
3
2
16

1
2
4
4
10
21

11
15
22
11
26
85

AML, acute myeloid leukemia; MDS, myelodysplastic syndromes; SAEs,
significant adverse events.

infections was noted in MDS patients (96.3%, P = 0.032).
However, AML patients also had shorter survival compared
with MDS patients (Fig. 1D). Therefore, patients who lived
longer and had more therapy tended to have more infection episodes, although developing multiple infections did
not affect the overall survival compared to patients who
only experienced one or two infections (Fig. 1B).
Blood count results were prospectively recorded on day
0, cycle 1 day 10 (C1D10), cycle 1 day 28 (C1D28), and
at the end of even cycles. Neutropenia was common across
all time-points (Fig. 1E). In total, 23%, 60%, and 69%
of patients had an ANC <0.1, <0.5, and <1.0 at two or
more measurements, respectively. At the time of each
infection-related SAE, the ANC was retrospectively assessed.
The majority of patients had neutropenia with ANC
<1.0 × 109/L (88.6%), or ANC <0.5 × 109/L (83%) at
the onset of infection, and more than half of the patients
(60.3%) presented with ANC <0.1 × 109/L (Fig. 1F).
For each event, the recorded admission for antibacterial,
antiviral, and antifungal prophylactic agents were reviewed
(Table 2). In the majority of admissions (74.8%, 122 of
163), the patients were documented as receiving antiviral

© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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Figure 1. Correlation of infection events with clinical features. (A) The incidence of infection-related events occurring within each cycle of therapy,
restricted to cycle numbers received by at least five patients. (B) Overall survival correlation with the number of infection-related SAEs a patient
experienced during therapy. (C and D) Correlation of age and disease with overall survival. P values indicate results of log-rank test. (E and F) Absolute
neutrophil count (ANC) at the schedule bone marrow biopsies and at the time of infection-related SAEs (ANC values indicate 109 neutrophils per liter).
Table 2. Prophylaxis at the time of infection.
Prophylaxis

Number
events

Class of
prophylaxis

Ciprofloxacin
Other antibiotics
Acyclovir
Other antivirals
Fluconazole
Other antifungal

74
14
101
21
51
17

Total antibiotics
Total antivirals
Total antifungals

Totals

88 (54%)
122 (74.8%)
68 (41.7%)

prophylaxis. Fewer patients were documented as receiving
antibacterial (54%) or antifungal prophylaxis (41.7%). Of
the admissions where patients were already receiving
© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

antibacterial prophylaxis, only 30% (27 of 90) had positive cultures for bacteria. In contrast, positive cultures
were noted in 42.8% (33 of 77) of the admissions of
patients with no antibacterial prophylaxis (P value: 0.08).
Furthermore, two of the six positive cultures for fungi
occurred in the setting of antifungal prophylaxis and five
of the eight viral infections occurred in patients receiving
antiviral prophylaxis (parainfluenza, HSV and rhinovirus/
enterovirus).

Causative agent
In 55.2% of the admissions (90 of 163), a clinically suspected
infection was associated with negative culture results. A
2817
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causative agent of infection was documented in 73 (44.8%)
of 163 admissions: gram-positive infections in 32 (19.6% of
total admissions), 20 (12.3%) were gram-negative, 12 (7.4%)
of admissions were associated with mixed infections (two
or more different pathogens), 6 (3.7%) were viral, two (1.2%)
were fungal, and 1 (0.6%) was mycobacterial. A total number
of 91 pathogens were retrieved from the infectious diagnostic
workups (cultures, swabs, etc. that were performed in these
73 admissions) (Table 3). Gram-positive bacteria represented
56% of the total isolated pathogens: coagulase-negative staphylococci including Staphylococcus epidermidis represented the
most common gram-positive organisms (23/91: 25.3%) followed by vancomycin-resistant enterococcus (VRE) (10/91:
11%). Pseudomonas species (8/91: 8.8%) followed by
Escherichia coli (6/91: 6.6%) were the most frequent gram-
negative pathogens. In the study population, 6 (6.6%) and
8 (8.8%) of the microbiology-
documented infections were
caused by fungal and viral agents respectively.

Site of infection
Lower respiratory tract infections were the most common
site for infection (28 events: 17.2% of all admissions).
This was followed by bacteremia (27 events: 16.6% of all
admissions) (Table 4).

Type of catheter
To understand whether indwelling catheters might influence the frequency and types of infections, we reviewed
admission chest X-
rays and procedure notes associated
with all 163 hospitalizations. In 101 of the 163 hospitalizations (62%), the patients had a central venous catheter
(Hohn). Twenty (12%) had implanted port, 20 (12%)
had peripherally inserted central catheters (PICC), and
22 (14%) had peripheral access. Patients who had Hohn
or PICC catheters tended to have more gram-
positive
infections compared to patients with other types of access
(port and peripheral access). However, this correlation
did not reach statistical significance (P = 0.47).

Infection susceptibility
Of the gram-positive organisms identified, vancomycin and
linezolid were most frequently associated with susceptibility.
In contrast, gram-negative organisms were most frequently
susceptible to cefepime, meropenem, and gentamycin.
Cefepime and vancomycin were the most commonly used
empiric antibiotics overall (56.25% of the admissions). Ten
of the Enterococcus cases (out of 12: 83.3%) were VRE.
Two of the Staphylococcus cases (out of 25: 8%) were
methicillin resistant (MRSA). One of the E. coli infections
was caused by extended-
spectrum beta-
lactamase
2818
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Table 3. Causative agent associated with infection.
Infection

Events

Gram-positive
MRSA
Coagulase-negative staph
Staphylococcus epidermidis
Others
Enterococcus
Vancomycin-sensitive
Vancomycin-resistant
Other
Viridans group
Corynebacterium
Lactobacillus
Clostridium difficile
Gram-negative
Pseudomonas
Escherichia coli
Enterobacteriaceae
Stenotrophomonas
B. fragilis
Achromobacter
Citrobacter
Mycobacteria
M. gordonae
Mycobacterium abscessus
Fungus
Candida
Aspergillus
Mucor
Fusarium
Curvularia
Viruses
Rhinovirus/enterovirus
Parainfluenza virus
HSV
Adenovirus
Coronavirus

Totals (%)
51/91 (56)

2
8
15
2
10
4
5
2
3
24/91 (26.4)
8
6
2
4
1
1
2
2/91 (2.2)
1
1
6/91 (6.6)
2
1
1
1
1
8/91 (9)
3
2
1
1
1

MRSA, methicillin resistant; HSV, herpes simplex virus.
Table 4. Site of infection.
Site

Events

Percent of
admissions

Lower respiratory
Peripheral blood
Central line
Wound or soft tissues
GI
Upper respiratory
Urinary

28
26
27
14
7
6
3

17%
16%
16.5%
9%
4.2%
4%
1.8%

GI, gastrointestinal.

(ESBL)-
producing organism. A prophylactic antibacterial
(ciprofloxacin 500 BID) was being administrated in five
cases (38.5%) of the 13 cases of resistant microorganisms
(MRSA, VRE, and ESBL) prior to admission. All the
Pseudomonas infections were sensitive to carbapenems.

© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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Infection outcome
Complete recovery from infectious complications was
observed in the majority of patients. The patients were
discharged on a prophylactic antibiotic (ciprofloxacin
500 mg BID) in 37.5% of the admissions. The length of
prophylaxis was indefinite in almost half of these cases.
During the study period, 10 (31.2%) of the gram-positive
and 3 (15%) of the gram-negative infections required readmission within 6 weeks. A total of seven deaths were attributed
to infection-related complications, with an overall incidence
of 8.2% (7 of 85 patients). Three deaths were due to gram-
negative bacteremia/sepsis (caused by Pseudomonas and ESBL-
producing E. coli), two due to pneumonia and acute respiratory
failure, one due to mixed bacteremia (Mycobacterium abscessus
and VRE), and one due to pneumonia associated with disseminated fusarium. Only one of these seven cases was on
prophylactic antibiotics prior to admission.

Effect of quinolone prophylaxis
Patients who were receiving quinolone prophylaxis at the
time of the SAE tended to have fewer positive cultures
compared to those who were not receiving prophylaxis (43%
vs. 57%); although this did not reach a statistical significance
(P = 0.084). The presence of antibiotics prophylaxis at the
time of admission was not associated with statistically significant higher rates of resistant microorganisms (P = 0.087)
or lower rates of mortality (P = 0.705). Two of the cases
of Clostridium difficile colitis occurred in the setting of
prophylactic ciprofloxacin treatment, and one did not.

Discussion
Relatively few precise data are available on the incidence
and characteristics of bacterial, fungal, and viral causes
of infections in AML and MDS patients treated with
decitabine [12, 13]. In this study, we investigated retrospectively the infectious complications that occurred in
85 patients with AML or MDS enrolled in NCT01687400.
In this study, we have described the prevalence and characteristics of clinically and microbiologically defined infections and infection-related mortality, and the relationship
between number of cycles and infection-related events as
well as the effect of prophylaxis on the positivity of cultures and susceptibility of microorganisms.
Neutropenia was common across all cycles of therapy
(Fig. 1E). Based on the frequency and duration of neutropenia observed in this cohort, current guidelines would
recommend consistent quinolone prophylaxis and consideration of antifungal prophylaxis [14, 15].
Infection-related grade 3–5 SAEs occurred in 70 of 85
patients (82%) during therapy, and were observed in

© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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approximately one third of patients during each cycle.
When compared to the incidence of infections when using
a 5-day decitabine regimen (29%) [9], longer courses of
therapy (10-day) were associated with more infections: 82%
in this study and 68% reported by Blum et al. [6]. However,
30-day mortality and 6-month survival remained comparable (2.4% vs. 7% and 63.5% vs. 60% in this cohort and
a cohort treated with the 5-day regimen, respectively) [9].
Fever and infections were the most frequent cause of
hospitalization in our patient population. The majority of
these events were not associated with a causative agent; an
identifiable organism was isolated in 45% of admissions
and bacteria represented the most commonly identified
source of infection. Microbiologically or clinically documented fungal or viral infections were diagnosed in less
than 5% of hospitalizations. In our study, the ratio of
gram-
positive to gram-
negative bacteria approached 2:1.
Gram-
positive cocci (predominantly coagulase-
negative
staphylococci) represented the most frequently isolated
microorganisms. This finding is not surprising, and consistent with the literature of other chemotherapeutic agents
in hematological malignancies as well as solid cancers [16,
17]. This dominant gram-positive pattern can be attributed
to the widespread use of indwelling intravascular catheters
and the use of prophylaxis targeted against gram-negative
organisms (e.g., ciprofloxacin). Surgically implanted tunneled
catheters have been associated with lower rates of bloodstream infections than percutaneously inserted catheters [18,
19]. In this study, we observed a nonsignificant trend toward
greater numbers of gram-positive infections in patients with
Hohn and PICC catheters, as might be expected. AML
and MDS patients receiving decitabine frequently present
with cytopenias and are unable to obtain a surgically
implanted catheter until they achieve remission. This limits
this opportunity for alternative access, and physicians should
be cognizant of the risks and opportunities posed by different forms of percutaneous access. Enterococcal species,
especially vancomycin-
resistant bacteria, represented the
second most common gram-positive isolates in our population, causing mainly bacteremia and urinary tract infections.
Nevertheless, the rate of VRE infections appears to be similar
in our patients compared to patients undergoing induction
with more intensive chemotherapy (11% compared to 10%)
[20, 21]. Although colonization is far more frequent than
true infection even in immunocompromised patients, bacteremia with VRE has been involved in outbreaks among
oncology patients treated with chemotherapy and can be
associated with increased mortality rates [20, 22].
Viridans group streptococci are other important pathogens
that are classically seen in patients undergoing induction
with high-dose intensive chemotherapy associated with neutropenia and oropharyngeal mucositis [23–26]. Four cases
of this type of bacteremia have been isolated in our patient
2819
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group (2.5%). Only one case had mucositis (rare with decitabine) at the time of bacteremia. Therefore, other ports of
entry, such as GI mucosa or central venous lines, may represent potential sources for these infections in these patients.
Infection-related mortality in our cohort was associated
with gram-negative bacteremia, pneumonia, and one case
of disseminated Fusarium. These data are consistent with
historical outcomes of aerobic gram-negative bacilli (E. coli
and Pseudomonas aeruginosa) [27, 28], and the focus of
our antibacterial prophylaxis targeted these bacteria.
Primary prophylaxis with fluoroquinolones in our patient
population was associated with a trend toward fewer positive blood cultures (P = 0.084), but was not associated
with higher rates of resistant microorganisms or lower
rates of mortality.
Fungal infections are an infrequent, but recurrent cause
of morbidity and mortality. We observed an incidence
of probable/proven invasive fungal infections of 7% including the mixed infections. Although the spectrum of the
fungal pathogens is similar (commonly, Aspergillus species
and Candida species), the incidence may be modestly
lower than the reported 12% incidence rate of IFIs in
AML patient treated with more intensive cytotoxic therapy
[29]. Nevertheless, considering the high number of observed
clinically suspected infections with negative cultures, we
cannot exclude that the incidence of invasive fungal infections might be higher.
Similar patterns of infectious complications have been
reported in AML patients during intensive chemotherapy.
A review of 747 adults with AML treated with conventional chemotherapy identified a source organism in 56.6%
of the febrile episodes [30]. Although bacterial infections
were also the most frequent cause of infectious complications (38.4%), more gram-negative infections were observed
(ratio 1:1), and a modestly higher incidence of fungal
infections was observed (13.8%) [29, 30].
In sum, we found that infection-
related SAEs were
common in AML and MDS patients undergoing a 10-
day decitabine regimen. In this cohort, admission to the
hospital for evaluation of neutropenic fever occurred in
the majority of patients at some point during treatment,
and occurred in nearly one third of patients during each
cycle of treatment. A causative agent was identified in
less than half of admissions, and gram-positive bacteria
were the most frequent agents identified. However, gram-
negative infections were associated with mortality.
Although expanding antimicrobial prophylaxis to include
better gram-
positive coverage (e.g., ampicillin or augmentin) could reduce the incidence of hospital admissions, this is unlikely to have an impact on overall survival.
Furthermore, the downsides of this approach including
toxicities and the potential for promoting resistance should
be considered. Prospective studies are needed to determine
2820
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whether the benefit of antibacterial prophylaxis outweighs
the risks.
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